

## 113 年雲嘉地區胸腔疾病聯合討論會

時間：民國 113 年 8 月 29 日(四) 18:30~20:30

地點：嘉義福容 Voco 酒店 3F 水仙廳(嘉義市世賢路一段 789 號 3F)

主辦單位：大林慈濟醫院胸腔內科

協辦單位：嘉義長庚醫院胸腔內科

嘉義基督教醫院胸腔內科

雲林台大醫院胸腔內科

台灣諾華股份有限公司

教育積分：台灣胸腔暨重症加護醫學會(申請中)

台灣肺癌學會 (申請中)

台灣臨床腫瘤醫學會(申請中)

時間	講題	講師	主持人
18:30	Opening Remark	大林慈濟醫院 賴俊良副院長	
18:30~19:30	Dabrafenib and Trametinib for the Treatment of BRAF V600E+ NSCLC.	臺大醫院 廖唯昱醫師	大林慈濟醫院 賴俊良副院長
19:30~20:30	Treatment Choice of SAA with Omalizumab and OCS Sparing Benefit in Real World Practice.	大林慈濟醫院 方科智醫師	大林慈濟醫院 陳信均主任
20:30	Closing Remark	大林慈濟醫院 陳信均主任	

臺大醫院 廖唯昱醫師

姓名	廖唯昱	Sex	<input checked="" type="checkbox"/> Male <input type="checkbox"/> Female
Name (in Print)	Wei-Yu, Liao	Date of Birth	1970-03-03
Education / Training ( Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training. )			
Institution and Location	Degree	Year(s)	Field of Study
National Taiwan University, College of Medicine	M.D., Ph.D.	1988-2014	Medicine

**Current Positions:**

Attending Physician, Department of Internal Medicine, National Taiwan University Hospital  
Clinical Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine

**Training and Working Experiences:**

1994-1995 Rotating Intern in National Taiwan University Hospital  
1995-2000 Resident, and Chief Resident, Department of Internal Medicine, National Taiwan University Hospital  
2001-now Attending Physician, Department of Internal Medicine, National Taiwan University Hospital  
2018-now Clinical Associate Professor, Department of Internal Medicine, National Taiwan University College of Medicine

**Professional Society:**

Member of Taiwan society of Internal Medicine  
Member of Taiwan society of Pulmonary and Critical Care Medicine  
Member of Taiwan Lung Cancer Society

**Selected peer-reviewed publications ( in chronological order ).**

1. **Liao WY**, Liaw YS, Wang HC, Chen KY, Luh KT, Yang PC. Bacteriology of infected cavitating lung tumor. *Am. J. Respir. Crit. Care Med.* 2000; 161:1750-1753.

2. Liao WY, Chen MZ, Chang YL, Wu HD, Yu CJ, Kuo PH, Yang PC. Ultrasound-guided transthoracic cutting biopsy for peripheral thoracic lesion less than 3 cm in diameter. *Radiology* 2000; 217:685-91.
3. Chen KY, Jerng JS, Liao WY, Ding LW, Kuo LC, Wang JY, Yang PC. Pneumothorax in the ICU: patient outcomes and prognostic factors. *Chest* 2002; 122:678-683.
4. Chang YL, Lee YC, Liao WY, Wu CT. The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. *Lung Cancer* 2004; 44:149-57.
5. Liao WY, Jerng JS, Chen MZ, Chang YL, Yang PC, Kuo SH. Value of imprint cytology for ultrasound-guided transthoracic core biopsy. *Eur. Respir. J.* 2004; 24:905-909.
6. Hsu TH, Liao WY, Yang PC, Wang CC, Xiao JL, Lee CH. Dynamics of cancer cell filopodia characterized by super-resolution bright-field optical microscopy. *Opt. Express* 2007; 15:76-82.
7. Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY, Chan WK, Chen HW, Yang PC. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. *Am. J. Respir. Crit. Care Med.* 2008; 177:763-770.
8. Huang CT, Liao WY. Emphysematous gastritis: A deadly infectious disease. *Scand. J. Infect. Dis.* 2009; 41:317-319. (Corresponding author)
9. Hsu TH, Yen MH, Liao WY, Cheng JY, Lee CH. Label-free quantification of asymmetric cancer-cell filopodium activities in a multi-gradient chip. *Lab Chip* 2009; 9:884-890.
10. Liao YC, Liao WY, Shun SC, Yu CJ, Yang PC, Lai YH. Symptoms, psychological distress, and supportive care needs in lung cancer patients. *Support Care Cancer.* 2011;19(11):1743-51.
11. Hsu TH, Xiao JL, Tsao YW, Kao YL, Huang SH, Liao WY, Lee CH. Analysis of the paracrine loop between cancer cells and fibroblasts using a microfluidic chip. *Lab Chip.* 2011;21;11(10): 1808-14.
12. Hsu TH, Kao YL, Lin WL, Xiao JL, Kuo PL, Wu CW, Liao WY, Lee CH. The

migration speed of cancer cells influenced by macrophages and myofibroblasts co-cultured in a microfluidic chip. *Integr Biol (Camb)*. 2012;4(2):177-82.

13. Liao WY, Shih JY, Chang GC, Cheng YK, Yang CH, Chen YM, Yu CJ. Genetic Polymorphism of XRCC1 Arg399Gln Is Associated with Survival in Non-Small-Cell Lung Cancer Patients Treated with Gemcitabine/Platinum. *J Thorac Oncolo*. 2012;7(6):973-81.
14. Huang CT, Tsai YJ, Liao WY, Wu PC, Ho CC, Yu CJ, Yang PC. Endobronchial ultrasound-guided transbronchial biopsy of peripheral pulmonary lesions: how many specimens are necessary? *Respiration*. 2012;84(2):128-34.
15. Wu SG, Yu CJ, Tsai MF, Liao WY, Yang CH, Jan IS, Yang PC, Shih JY. Survival of lung adenocarcinoma patients with malignant pleural effusion. *Eur Respir J*. 2012 Sep 27 (In Press)
16. Huang CT, Ruan SY, Liao WY, Kuo YW, Lin CY, Tsai YJ, Ho CC, Yu CJ. Risk factors of pneumothorax after endobronchial ultrasound-guided transbronchial biopsy for peripheral lung lesions. *PLoS One*. 2012;7(11):e49125
17. Huang JW, Pan HJ, Yao WY, Tsao YW, Liao WY, Wu CW, Tung, YC, Lee CH. Interaction between lung cancer cell and myofibroblast influenced by cyclic tensile strain *Lab Chip*. 2013 Mar 21;13(6):1114-20.
18. Lee YH, Liao YC, Liao WY, Shun SC, Liu YC, Chan JC, Yu CJ, Yang PC, Lai YH. Anxiety, depression and related factors in family caregivers of newly diagnosed lung cancer patients before first treatment. *Psychooncology*. 2013;22(11):2617-23.
19. Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. *Clin Lung Cancer*. 2013 Jul;14(4):418-24.
20. Tsai TH, Yang CY, Ho CC, Liao WY, Jan IS, Chen KY, Wang JY, Ruan SY, Yu CJ, Yang JC, Yang PC, Shih JY. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. *Lung Cancer*. 2013;82(3):420-5.

21. Liao YC, Shun SC, Liao WY, Yu CJ, Yang PC, Lai YH. Quality of life and related factors in patients with newly diagnosed advanced lung cancer: a longitudinal study. *Oncol Nurs Forum*. 2014 Mar 1;41(2):E44-55.
22. Tseng JS, Yang TY, Chen KC, Hsu KH, Yu CJ, Liao WY, Tsai CR, Tsai MH, Yu SL, Su KY, Chen JJ, Chen HY, Chang GC. Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. *Onco Targets Ther*. 2014 May 23;7:799-805.
23. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, Liao WY, Yang PC, Yang JC. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. *J Thorac Oncol*. 2014 Sep;9(9):1385-92.
24. Liao WY, Ho CC, Hou HH, Hsu TH, Tsai MF, Chen KY, Chen HY, Lee YC, Yu CJ, Lee CH, Yang PC. Heparin co-factor II enhances cell motility and promotes metastasis in non-small cell lung cancer. *J Pathol*. 2015 Jan;235(1):50-64.
25. Potprommanee L, Ma HT, Shank L, Juan YH, Liao WY, Chen ST, Yu CJ. GM2-activator protein: a new biomarker for lung cancer. *J Thorac Oncol*. 2015 Jan;10(1):102-9.
26. Gow CH, Liao WY, Liu YN, Shih JY. Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib. *J Thorac Oncol*. 2015 Jul;10(7):e58-60.
27. Tseng CH, Chen KC, Hsu KH, Tseng JS, Ho CC, Hsia TC, Su KY, Wu MF, Chiu KL, Liu CM, Wu TC, Chen HJ, Chen HY, Chang CS, Hsu CP, Hsia JY, Chuang CY, Lin CH, Chen JJ, Chen KY, Liao WY, Shih JY, Yu SL, Yu CJ, Yang PC, Yang TY, Chang GC. EGFR mutation and lobar location of lung adenocarcinoma. *Carcinogenesis*. 2016 Feb;37(2):157-62.
28. Chen SC, Chiou SC, Yu CJ, Lee YH, Liao WY, Hsieh PY, Jhang SY, Lai YH. The unmet supportive care needs-what advanced lung cancer patients' caregivers need and related factors. *Support Care Cancer*. 2016 Jul;24(7):2999-3009.

29. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, Rosell R, Yang PC. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. *Lung Cancer*. 2016 Apr;94:46-53.
30. Lin CH, Hsieh SC, Keng LT, Lee HS, Chang HT, Liao WY, Ho CC, Yu CJ. Prospective Evaluation of Procalcitonin, Soluble Triggering Receptor Expressed on Myeloid Cells-1 and C-Reactive Protein in Febrile Patients with Autoimmune Diseases. *PLoS One*. 2016 Apr 20;11(4)
31. Kao YC, Jheng JR, Pan HJ, Liao WY, Lee CH, Kuo PL. Elevated hydrostatic pressure enhances the motility and enlarges the size of the lung cancer cells through aquaporin upregulation mediated by caveolin-1 and ERK1/2 signaling. *Oncogene*. 2016 Aug 8.
32. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang CH, Yu CJ MD. Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced NSCLC patients treated with first-line gefitinib. *The Oncologist* 2017 May (Corresponding author)
33. Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. *Radiother Oncol* 2017, Oct, S0167-8140(17)32650-6.
34. Liao YC, Liao WY, Sun JL, Ko JC, Yu CJ. (). Psychological distress and coping strategies among women with incurable lung cancer: a qualitative study. *Support Care Cancer*. 2018 Mar;26(3):989-996.
35. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC. (2017, Dec).

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.  
Lancet Respir Med, 2018 Feb;6(2):107-116.

36. **Liao WY**, Ho CC, Tsai TH, Chen KY, Shih JY, Yu CJ. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum. Lung Cancer. 2018 Apr;118:90-96.
37. Lin SY, Yang CY, Liao BC, Ho CC, **Liao WY**, Chen KY, Tsai TH, Hsu CL, Hsu WH, SuK Y, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. J Cancer. 2018 Apr19;9(10):1813-1820
38. Yu KL, Tsai TH, Ho CC, **Liao WY**, Lin CK, Hsu CL, Shih JY. The value of radial endobronchial ultrasound-guided bronchial brushing in peripheral non-squamous non-small cell lung cancer. Sci Rep. 2018 Apr 11;8(1):5837.
39. Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, **Liao WY**, Gautschi O, Spataro V, Unk M, Chih-Hsin Yang J, Lorence RM, Carrière P, Cseh A, Chang GC. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. J Thorac Oncol. 2018 Aug 7.
40. Lin YT, Chen JS, **Liao WY**, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. Clinical Outcomes and Secondary Epidermal Growth Factor Receptor (EGFR) T790M Mutation among First-line Gefitinib, Erlotinib and Afatinib-treated Non-small Cell Lung Cancer Patients with Activating EGFR Mutations. Int J Cancer. 2019 Jun 1;144(11): 2887-2896. (Corresponding author)
41. Yang CY, Hsieh MS, **Liao WY**, Shih JY, Yu CJ. Consecutive Emergence of Typical Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in a Patient With Metastatic Pulmonary Squamous Cell Carcinoma. J Oncol Pract. 2019 Feb;15(2):115-118. (Corresponding author)
42. Lee JH, Chen HY, Hsu FM, Chen JS, **Liao WY**, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC. Cranial Irradiation for Patients with Epidermal Growth

Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. *Oncologist*. 2019 May 24

43. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. *Eur J Cancer*. 2019 Aug;117:107-115. (Corresponding author)
44. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association Between Programmed Death-Ligand 1 Expression, Immune Microenvironments, and Clinical Outcomes in Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Patients Treated With Tyrosine Kinase Inhibitors. *Eur J Cancer* 2020 Jan;124:110-122.
45. Cho SL, Lin WC, Chuang CA, Liao WY, Lai CF. Tubulointerstitial nephritis associated with erlotinib therapy for lung cancer. *Nephrology (Carlton)*. 2020;25(9):730.
46. Yang CY, Liao WY, Ho CC, et al. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib [published online ahead of print, 2020 May 9]. *Oncologist*. 2020;25(8):702-711.
47. Liao BC, Hsu WH, Lee JH, Yang CY, Tsai TH, Liao WY, Ho CC, Lin CC, Shih JY, Yu CJ, Soo RA, Yang JC. Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M-Positive NSCLC. *JTO Clin Res Rep*. 2020 Sep 19;2(1):100099.
48. Hou HH, Pan HJ, Liao WY, Lee CH, Yu CJ. Autophagy in fibroblasts induced by cigarette smoke extract promotes invasion in lung cancer cells. *Int J Cancer*. 2020 Nov 1;147(9):2587-2596.
49. Wu SG, Liao WY, Su KY, Yu SL, Huang YL, Yu CJ, Chih-Hsin Yang J, Shih JY. Prognostic Characteristics and Immunotherapy Response of



Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan. *JTO Clin Res Rep*. 2020 Dec 26;2(2):100140.

50. Huang YH, Hung JY, Ko HW, Su PL, Lai CL, Chang HC, Hsia TC, Lin SH, Wu KL, Yang CT, Su WC, Chu YC, Wang CC, Liao WY, Lin YT, Lin CH, Lin MC, Hsu KH, Tseng JS, Yang TY, Chen KC, Lee MH, Yu SL, Ho CC, Chang GC. The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study. *Ther Adv Med Oncol*. 2021 May 22;13:17588359211018022.
51. Hsu CL, Tsai TH, Huang CK, Yang CY, Liao WY, Ho CC, Ruan SY, Chen KY, Shih JY, Yang PC. Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer. *Lung Cancer*. 2021 Jun;156:50-58.
52. Chang CL, Hsieh MS, Shih JY, Lee YH, Liao WY, Hsu CL, Yang CY, Chen KY, Lee JH, Ho CC, Tsai TH, Yang JC, Yu CJ. Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma. *Ther Adv Med Oncol*. 2022 Oct 27;14:17588359221133889. (Corresponding author)
53. Pan HY, Lee CW, Wu LY, Hsu HH, Tung YC, Liao WY, Lee CH. A 3D culture system for evaluating the combined effects of cisplatin and anti-fibrotic drugs on the growth and invasion of lung cancer cells co-cultured with fibroblasts. *APL Bioeng*, in press. (Corresponding author)

摘要：

Dabrafenib and Mekinist 用於 BRAF V600E+ NSCLC 的臨床試驗資料回顧  
與健保給付後的治療現況討論。

BRAFV600E mutation occurs in 1-2% of lung adenocarcinomas and acts as an oncogenic driver. Dabrafenib, alone or combined with trametinib, has shown substantial antitumour activity in patients with previously treated BRAFV600E-mutant metastatic non-small-cell lung cancer (NSCLC). We aimed to assess the activity and safety of dabrafenib plus trametinib treatment in previously untreated patients with BRAFV600E-mutant metastatic NSCLC.

Dabrafenib plus trametinib represents a new therapy with clinically meaningful antitumour activity and a manageable safety profile in patients with previously untreated BRAFV600E-mutant NSCLC.

大林慈濟醫院 方科智醫師

現職：胸腔內科醫師兼 7A 病房主任

### 經歷

成大醫院內科部住院醫師

大林慈濟醫院胸腔內科總醫師

大林慈濟醫院胸腔內科研究醫師

大林慈濟醫院胸腔內科副主治醫師

### 學歷

高雄醫學大學醫學系

### 治療專長

1. 咳嗽、喘、胸痛、氣喘、慢性阻塞性肺疾病
2. 肺炎、肺結核、睡眠呼吸中止症
3. 肺癌、胸肺部及縱膈腔腫瘤、一般內科疾病

摘要：

Omalizumab 針對 OCS burden 對於 SAA 的病患族群在臨床試驗資料的分析為何？

The current evidence on the treatment benefits of omalizumab in patients with IgE levels >1500 IU/mL. The findings from the reviewed studies which included >3000 patients support the efficacy and effectiveness of omalizumab in reducing exacerbations, and improving asthma control, lung function, and quality of life in patients with severe asthma having IgE levels beyond the current dosing range. Omalizumab was well-tolerated in these patients, with no new safety signals. In addition, high IgE levels

(>1500 IU/mL) are also reported in several comorbidities of asthma (allergic rhinitis, atopic dermatitis, allergic bronchopulmonary aspergillosis [ABPA], food allergy, and nasal polyposis) and omalizumab has demonstrated efficacy and safety in these indications.